Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HER2-mutant NSCLC. In this educational program, these experts use case-based discussions, focused data presentations, and expert panel discussions to help clinicians translate emerging HER2-directed evidence into practical treatment strategies for patients with HER2-mutant NSCLC.
This educational activity is an archive of the live symposium held on October 26, 2026.
Target Audience
This educational activity is directed toward oncologists, advanced practice providers, nurses, pharmacists, and other health care providers involved in the diagnosis and treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify current best practices for HER2 biomarker testing in NSCLC, including assay selection, timing, and integration into clinical workflows.
- Evaluate recent and emerging clinical trial data supporting the use of HER2-directed therapies in HER2-mutant NSCLC.
- Develop personalized treatment strategies for patients with HER2-mutant NSCLC, incorporating evidence-based sequencing decisions, management of intracranial disease, and proactive mitigation of treatment-related toxicities.
Solange Peters, MD, PhD
Full Professor
Chair, Medical Oncology and Oncology Thoracic Malignancies Program
University Hospital of Lausanne
Lausanne, Switzerland
Disclosures: Advisor, Consultant, Speaker, Fee-for-Service Recipient: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, Eli Lilly and Company, F-star Therapeutics, Foundation Medicine, Genmab, Genzyme, Gilead Sciences, GSK, HUTCHMED, Illumina, Incyte, Ipsen, iTeos Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Novocure, Nuvalent, Nuvation Bio, Nykode Therapeutics, Pfizer, PharmaMar, Promontory Therapeutics, Regeneron, Roche/Genentech, Sanofi, Takeda, Zymeworks; Speakers Bureau (all fees to institution): AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda; Grant/Research Funding (Principal Investigator in trials; all fees to institution): Amgen, Arcus, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, GSK, iTeos Therapeutics, Merck Sharp and Dohme, Mirati, Pfizer, PharmaMar, Promontory Therapeutics, Roche/Genentech.
Enriqueta Felip, MD, PhD
Professor of Medicine
Universitat Autònoma de Barcelona
Section Chief, Medical Oncology Department
Head, Thoracic Tumors Group
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Ellipses Pharma, Gilead Sciences, GSK, iTeos Therapeutics, Johnson & Johnson, Merck, Moderna, Pfizer, PharmaMar, Pierre Fabre Laboratories, Regeneron, Roche, Tubulis GmbH.
Balazs Halmos, MD, MS
Professor of Clinical Medicine
Associate Director for Clinical Science
Montefiore Einstein Comprehensive Cancer Center
Director of Thoracic Oncology
Albert Einstein College of Medicine/Montefiore Einstein
Bronx, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Genentech, GSK, Ipsen, Johnson & Johnson, Merck & Co., Inc., Nuvalent, Pfizer, Takeda; Grant/Research Funding: AbbVie, Amgen, ArriVent BioPharma, AstraZeneca, BioNTech, Black Diamond Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Henlius Therapeutics, Janssen, Jazz Pharmaceuticals, Merck & Co., Inc., Pfizer, Revolution Medicines, Zai Lab.
Xiuning Le, MD, PhD
Associate Professor
Deputy Section Chief, Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Fee-for-Service Recipient: AbbVie, ABION, Akeso, Allist, ArriVent BioPharma, AstraZeneca, Avistone, Bayer, BioNTech, BlossomHill, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Dizal Pharma, Eli Lilly and Company, EMD Serono, Hengrui, Innovent, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, Regeneron Pharmaceuticals, Summit Therapeutics, SystImmune, Taiho Oncology, Teligene; Grant/Research Funding (to institution): ArriVent BioPharma, Dizal Pharma, Eli Lilly and Company, EMD Serono, Johnson & Johnson, Regeneron Pharmaceuticals, Takeda, Teligene, Thermo Fisher.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here